AzTrials
AzTrials

Cystic FibrosisProspectiveNCT04395820

Prospective Surveillance of Lung Development During Childhood, Adolescence and Adulthood in Healthy and Patients With Cystic Fibrosis

An observational study of Cystic Fibrosis and Healthy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Cystic fibrosis (CF) is the most common lethal inherited disease in Caucasian populations. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood. Read more about this study

Who is it for?
Ages 3 to 18 yearsHealthy volunteers can take part
Conditions the study is for
Cystic Fibrosis, Healthy
What is being tested?
Lung function test and Imaging
How many people
250 participants
Where
1 siteSwitzerland
Study dates
1 Jul 2020to 1 Dec 2100
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: Children and adults with CF and healthy volunteers from the local community in Bern and surrounding areas.

Who may be able to join

  • Individuals with CF:
  • Diagnosis of CF
  • Signed written informed consent
  • ≥3 - 18 years of age, depending on the cooperation and if lung function measurements are possible
  • Healthy volunteers:
  • Signed written informed consent
Show all 9Show fewer
  • Informed consent of participant and if under 18 years, legal representative respectively
  • Children and adults with no history of chronic lung disease or acute respiratory infection in the four weeks prior to the study visit
  • ≥3 - 18 years of age, depending on the cooperation and if lung function measurements are possible

Who cannot join

  • The presence of any one of the following exclusion criteria will lead to exclusion of the participant, for example:
  • Women who are pregnant or breast feeding.
  • Intention to become pregnant during the course of the study
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
  • Please note that female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
  • Other clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, etc.)
Show all 19Show fewer
  • Known or suspected non-compliance, drug or alcohol abuse
  • Continuous glucose monitor
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the participant
  • Metal in body, e.g. pacemaker
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Subjects which are respiratory insufficient to attend on the lung function measurements (oxygen demand)
  • Subjects who are unable to perform the MRI without sedation
  • Participants which were born preterm (<36. week of pregnancy)
  • Current smokers
  • In addition for individuals with CF:
  • Known diseases other than related to CF
  • In addition for healthy individuals:
  • Current upper respiratory infection (cough, cold, fever) will lead to postponement of the visit to 4 weeks after the end of symptoms

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Children's Hospital Bern

    Bern, 3010

Other trials in Switzerland

About this study

Cystic fibrosis (CF) is the most common lethal inherited disease in Caucasian populations. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood.

Therefore the overall objective is to prospectively assess the clinical utility of novel and non-invasive measuring methods, namely Multiple Breath Washout and functional lung MRI in the longitudinal clinical surveillance of patients with CF and compare the results to those of healthy controls.

Read the detailed description

Background and project rationale:

Cystic fibrosis (CF), the most common lethal inherited disease in Caucasian populations, affects approximately 1:2500 live births. It is a multisystem disorder with respiratory morbidity and mortality being the leading cause of death. Despite improved survival in successive birth cohorts, the current median survival age of patients with CF is about 40 years. To improve survival, it is essential to understand the development, progression and treatment of CF lung disease throughout early childhood. Therefore tracking of lung function throughout childhood may provide important insights into the development and progression of CF lung disease. Spirometry, the standard lung function test for decades, is sensitive only for airflow limitation arising in large airways and insensitive for assessment of small or peripheral airway involvement, whereby the CF lung disease emerges in the small airways. Two promising techniques to assess small airway function in young children include the multiple breath washout (MBW) lung function test and functional Matrix-Pencil magnetic resonance imaging (MP-MRI).

Project Objectives and Design:

The overall objective of this project is to prospectively assess the clinical utility of MBW and MP-MRI in the longitudinal clinical surveillance of patients with CF. Therefore this study: i) Examines differences in MBW and MP-MRI outcomes between patients with CF and healthy controls. ii) Assesses the short term (over 1h) repeatability of MBW and MP-MRI outcomes in patients with CF and healthy controls. iii) Assesses whether MBW and MP-MRI outcomes are associated with clinical lung disease in patients with CF. iv) Determines whether changes in MBW and MP-MRI outcomes are associated with progression of lung disease in patients with CF. v) Compares the breath-by-breath regional and temporal changes in functional MRI signal with breath-by-breath changes in MBW phase outcomes in patients with CF and healthy controls.

Methods:

Data of MBW, MP-MRI, morphological MRI, Spirometry and body plethysmography, clinical respiratory symptoms and microbiology will be collected during this study.

Recruitment and participation:

Children and adults with CF will be recruited from the outpatient and inpatient clinics at the Inselspital in Bern. Healthy controls will be recruited from the local community in Bern and surrounding areas.

Information collected:

Lung function:

  • Multiple Breath Washout (FRC, LCI, Scond, Sacin)
  • Spirometry (FEV1, FVC, FEFx)
  • Body plethysmography (sReff, FRCpletz, TLC)

Respiratory symptoms and clinical data:

CF:

  • respiratory symptoms (cough, sputum characteristics, shortness of breath, weight loss, appetite fatigue)
  • clinical data (increased work of breathing, hypoxemia, wheeze, crackles, differential air entry)

Healthy controls:

Presence of respiratory symptoms in the last four weeks preceding visit.

Functional and structural MRI:

  • Functional MRI (percentage of the lung volume with impaired fractional ventilation (RFV) and relative perfusion (RQ)
  • Structural MRI( Eichinger MRI scoring system to assess the presence and extent of bronchiectasis, mucous plugging, and air trapping)

Medical history:

CF: demographics, genetic mutation, pulmonary exacerbations, hospitalisations, regular therapy and medication, complications, microbiological data and laboratory reports

Microbiology:

CF: bacterial analysis of oropharyngeal swabs

Quality of life:

CF: CF-specific quality of life and symptoms

Sputum:

CF:

  • spontaneously expectorated sputum
  • Induced sputum

Study database:

All study data is recorded in an Access-database with SQL Servers. The database is accordant to the HFG and was adapted together with the CTU.

Funding:

The Swiss National Foundation (32003B_182719) and Vertex-Pharmaceuticals Cystic Fibrosis Research Innovation Award provide financial and material support for this observational study

Being tested
Lung function test, Imaging
Keywords
Cystic Fibrosis, MBW, MRI, Airway growth, Airway development, Healthy
Medical subject headings
Cystic Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lung function testDiagnostic test

    MBW

  • ImagingDiagnostic test

    MP-MRI

Study groups in NCT04395820
Study groupRoleWhat they receive
Cystic FibrosisNot described
Receives: Diagnostic Test: Lung function test; Diagnostic Test: Imaging
HealthyNot described
Receives: Diagnostic Test: Lung function test; Diagnostic Test: Imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Multiple Breath Washout

    Longitudinal assessment of lung volume and ventilation inhomogeneity

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  2. Functional MP-MRI

    Longitudinal assessment of percentage of the lung volume with impaired fractional ventilation and relative perfusion

    Measured: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points).

Secondary outcomes (12)
  1. Morphological MRI

    Longitudinal assessment of the presence and extent of bronchiectasis, mucous plugging and air trapping by Eichinger MRI scoring.

    Measured: Every twelfth month up to 50 years. Healthy controls only during 1 year (2 time points)

  2. Spirometry: FEV1

    Longitudinal assessment of forced expired volume in 1 second.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  3. Spirometry: FVC

    Longitudinal assessment of forced vital capacity.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  4. Spirometry: FEF

    Longitudinal assessment of forced expiratory flows.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  5. Body plethysmography: sRAW

    Longitudinal assessment of specific airway resistance.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  6. Body plethysmography: FRC

    Longitudinal assessment of functional residual capacity.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  7. Body plethysmography: TLC

    Longitudinal assessment of total lung capacity.

    Measured: Every third month up to 50 years. Healthy controls only during 1 year.

  8. Respiratory symptoms

    Longitudinal assessment of clinical respiratory symptoms.

    Measured: Every third month up to 50 years. Only CF patients.

  9. Exacerbations

    Longitudinal assessment of clinical status.

    Measured: Every third month up to 50 years. Only CF patients.

  10. CF-related quality of life

    Longitudinal assessment of standardised age-specific CF-related quality of life questions.The scale goes from 0-100, higher score means better outcome.

    Measured: Every third month up to 50 years. Only CF patients.

  11. Microbiology: presence of respiratory pathogens

    Longitudinal assessment of presence of respiratory pathogens from oropharyngeal swabs and sputum samples.

    Measured: Every third month up to 50 years. Only CF patients.

  12. Microbiology: abundance of respiratory pathogens

    Longitudinal assessment of abundance of respiratory pathogens from oropharyngeal swabs and sputum samples.

    Measured: Every third month up to 50 years. Only CF patients.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2020
  2. Study start1 Jul 2020
  3. Primary completion1 Dec 2050 (estimated)
  4. Study completion1 Dec 2100 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04395820
Sponsor's protocol ID
2019-01591
Other IDs
2019
Acronym
Prospective
Status last verified
Nov 2020
First submitted
5 May 2020
Last updated
4 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5. Epub 2009 May 4.

    PubMed 19403164
  • Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, Robins-Browne RM, Franklin PJ, de Klerk NH, Sly PD, Stick SM, Hall GL; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med. 2014 Nov 15;190(10):1111-6. doi: 10.1164/rccm.201407-1277OC.

    PubMed 25321321

Questions about this trial

What is this clinical trial studying?

An observational study of Cystic Fibrosis and Healthy, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 4 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Multiple Breath Washout (time frame: Every third month up to 50 years. Healthy controls only during 1 year.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04395820, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in